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Over the past two decades, our understanding of the endocannabinoid system has
greatly improved due to the wealth of results obtained from exploratory studies. Currently,
two cannabinoid receptor subtypes have been well-characterized. The cannabinoid
receptor type 1 (CB1) is widely expressed in the central nervous system, while the
levels of the cannabinoid receptor type 2 (CB2) in the brain and spinal cord of healthy
individuals are relatively low. However, recent studies demonstrated a CB2 upregulation
on activated microglia upon neuroinflammation, an indicator of neurodegeneration. Our
research group aims to develop a suitable positron emission tomography (PET) tracer
to visualize the CB2 receptor in patients suffering from neurodegenerative diseases.
Herein we report two novel thiophene-based 11C-labeled PET ligands designated
[11C]AAT-015 and [11C]AAT-778. The reference compounds were synthesized using
Gewald reaction conditions to obtain the aminothiophene intermediates, followed by
amide formation. Saponification of the esters provided their corresponding precursors.
Binding affinity studies revealed Ki-values of 3.3 ± 0.5 nM (CB2) and 1.0 ± 0.2
µM (CB1) for AAT-015. AAT-778 showed similar Ki-values of 4.3 ± 0.7 nM (CB2)
and 1.1 ± 0.1 µM (CB1). Radiosynthesis was carried out under basic conditions
using [11C]iodomethane as methylating agent. After semi-preparative HPLC purification
both radiolabeled compounds were obtained in 99% radiochemical purity and the
radiochemical yields ranged from 12 to 37%. Specific activity was between 96 and 449
GBq/µmol for both tracers. In order to demonstrate CB2 specificity of [
11C]AAT-015 and
[11C]AAT-778, we carried out autoradiography studies using CB2-positive mouse/rat
spleen tissues. The obtained results revealed unspecific binding in spleen tissue
that was not blocked by an excess of CB2-specific ligand GW402833. For in vivo
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analysis, [11C]AAT-015 was administered to healthy rats via tail-vein injection. Evaluation
of the CB2-positive spleen, however, showed no accumulation of the radiotracer.
Despite the promising in vitro binding affinities, specific binding of [11C]AAT-015, and
[11C]AAT-778 could not be demonstrated.
Keywords: cannabinoid receptor type 2, neuroinflammation, positron emission tomography, neurodegenerative
disorders, thiophene-based structures
INTRODUCTION
Cannabinoid receptors belong to the large family of G
protein-coupled receptors (GPCRs) exhibiting the characteristics
of a glycosylated extracellular N-terminus, seven transmembrane
α-helixes, and an intracellular C-terminus (Mackie, 2008; Rom
and Persidsky, 2013). They are key players in a series of
physiological processes resulting in an overall auto-protective
effect in mammalians (Pertwee, 2005). Currently, there are
two well-characterized subtypes of the cannabinoid receptor
(CB1 and CB2) that share 44% sequence similarity and differ
substantially in their expression profiles (Pertwee, 1997). The
CB1 receptor is mainly expressed in the central nervous system
(CNS), CB2 is predominantly found in peripheral immune
cells (Matsuda et al., 1990; Herkenham et al., 1991; Maresz
et al., 2005; Chin et al., 2008). Under physiological conditions,
the CB2 receptor expression in the brain and the spinal cord
is barely detectable (Van Sickle et al., 2005). However, there
are several studies demonstrating an upregulation of CB2 on
activated microglial cells (macrophages of the CNS), rendering
the receptor a promising target to exploit neuroinflammatory
changes involved in neurodegenerative disorders such asmultiple
sclerosis, amyotrophic lateral sclerosis (ALS), Parkinson’s or
Alzheimer’s disease (Benito et al., 2008; Onaivi, 2009).
The various implications of the CB2 receptor as well as
the fact that it is only marginally expressed in the CNS of
healthy subjects make it a promising target for diagnostic and
clinical applications. The development of a successful CB2 PET
ligand might improve our understanding of the mechanisms
underlying disease pathogenesis as well as provide a tool for
therapy monitoring and development of novel therapeutic drug
candidates. In particular, this would be beneficial for patients
suffering from rare diseases with no current effective drug
treatment like ALS (Zinman and Cudkowicz, 2011). Several CB2
radioligands have been published by various research groups
but till now, none of these radioligands has been found to
be useful in the clinics. Their limitations included lack of
selectivity over CB1, high lipophilicity, low brain uptake due
to P-glycoprotein eﬄux, brain penetrating radiometabolites,
and trapped radiometabolites (Evens et al., 2008; Horti et al.,
2010; Vandeputte et al., 2011; Hortala et al., 2014). Our
research group is interested in evaluating different structural
scaffolds in order to determine potential candidate compounds
as CB2-specific radioligands. In our previous work, we reported
the development of oxoquinoline- as well as pyridine-based
CB2 radiotracers (Mu et al., 2013, 2014; Slavik et al., 2015a,b).
Recently, a new class of thiophene amide derivatives emerged
as potent and selective CB2 agonists (Nelson et al., 2012).
Several studies have been conducted to show the therapeutic
applicability of thiophene-based derivatives in painmanagement,
but this class of compounds has not yet been tested within the
context of neurodegeneration. Herein we report the development
of two novel thiophene-based PET radioligands designated
[11C]AAT-015 and [11C]AAT-778 for a diagnostic approach
toward CB2 receptor imaging.
MATERIALS AND METHODS
All animal experiments were carried out in accordance with the
Swiss AnimalWelfare legislation and approved by the Veterinary
Office of the Canton Zurich. MaleWistar rats andmale CD1mice
were purchased from Charles River Laboratories (Sulzfeld, DE)
and kept under standard conditions.
All chemicals, unless otherwise stated, were purchased
from Sigma Aldrich GmbH (Taufkirchen, DE), ABCR GmbH
(Karlsruhe, DE), Merck (Darmstadt, DE), or Fluka (Buchs,
CH) and were used without further purification. Solvents for
thin layer chromatography (TLC), column chromatography
and extractions were purchased as commercial grade. Organic
chemistry reactions were monitored by TLC using Sigma-
Aldrich silica gel 60 plates under UV light at 254 nm. Nuclear
magnetic resonance (NMR) spectra (1H and 13C NMR) were
obtained on a Bruker Avance FT-NMR spectrometer (400 MHz).
Chemical shifts are given in delta (δ) units, in ppm relative to
tetramethylsilane (TMS, 0 ppm). Multiplicities in the 1H NMR
spectra are described as: s = singlet, d = doublet, t = triplet,
m = multiplet and br = broad peak. Coupling constants (J) are
reported in Hz. High resolution mass spectrometry (HRMS) was
performed on a Bruker’s maXis (ESI-Qq-TOF-MS) spectrometer
(Bruker Daltonik GmbH, DE) and are given in m/z.
High-performance liquid chromatography (HPLC) analysis
were performed using a reversed phase column (ACE column,
C18, 3 µm) with a gradient system of acetonitrile and
0.1% trifluoroacetic acid in water. Analytical radio-HPLC was
performed with a flow rate of 1 mL/min on an Agilent 1100
series system equipped with a Raytest Gabi Star radiodetector
(Agilent Technologies, Morges, CH). Semi-preparative HPLC
purifications were carried out using a reversed phase column
(ACE column, Symmetry C8 5 µm; 7.8 × 50 mm) under the
following conditions: 0.1% H3PO4 in H2O (solvent A), MeCN
(solvent B); 0.0–8.0 min, 20% B; 8.1–30.0 min, 20–90% B;
30.1–32.0 min, 90% B; 32.1–34.0 min, 90–20% B; 34.1–40.0
min, 20% B; flow rate: 4 mL/min. Specific activity was
calculated by comparing ultraviolet peak intensity of the final
formulated products with calibration curves of corresponding
non-radioactive standards of known concentrations.
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Chemistry
Methyl 2-amino-5-methyl-4-propylthiophene-3-
carboxylate (1)
Morpholine (0.87 mL, 10 mmol) was added to a mixture of
3-hexanone (1.0 g, 10 mmol), methyl cyanoacetate (0.88 mL,
10 mmol) and sulfur (0.32 g, 10 mmol) in MeOH (5 mL).
The mixture was refluxed overnight, then cooled to room
temperature and poured into ice water. The resulting precipitate
was filtered and the solid was then dissolved in dichloromethane.
The solution was dried over anhydrous sodium sulfate and
evaporated to dryness. The residue was purified by flash column
chromatography on silica gel using petroleum ether/ethyl acetate
(9:1) as eluent to give the title compound (230 mg, 11%) as
a white solid. 1H NMR (400 MHz, DMSO-d6): δ 7.14 (s, 2H),
3.68 (s, 3H), 3.32 (s, 3H), 2.54 (t, J = 7.4 Hz, 2H), 1.38 (m,
2H), 0.85 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz, DMSO-
d6): δ 165.0, 162.4, 136.2, 112.5, 103.0, 50.3, 29.6, 23.2, 13.9,
12.0. HRMS calculated for C10H16NO2S (M+H) 214.0896, found
214.0897.
Methyl 2-(adamantane-1-carboxamido)-5-methyl-4-
propylthiophene-3-carboxylate (AAT-778)
A solution of 1-adamantane-carbonyl chloride (240 mg, 1.22
mmol) in dry 1,4-dioxane (3 mL) was added dropwise to a
solution of compound 1 (200 mg, 0.94 mmol) in 10 mL of
the same solvent while maintaining the reaction temperature
at 70◦C. After the addition was completed, the solution was
stirred at 100◦C for 2 h and then concentrated under reduced
pressure. The residue was dissolved in dichloromethane, washed
with aq. HCl (1M) and NaHCO3 (saturated solution), dried
over anhydrous sodium sulfate and evaporated to dryness. The
crude product was purified by flash column chromatography
on silica gel and eluted with petroleum ether/ethyl acetate
(9:1). Subsequent recrystallization from MeOH gave the title
compound (166 mg, 47%). 1H NMR (400 MHz, CDCl3): δ
11.6 (s, 1H), 3.9 (s, 3H), 2.7 (t, J = 6.7 Hz, 2H), 2.2 (s, 3H),
2.1 (m, 3H), 2.0 (m, 7H), 1.8 (m, 7H), 1.5 (m, 2H), 0.9 (t, J
= 6.7 Hz, 2H). 13C NMR (100 MHz, CDCl3): δ 175.3, 167.1,
148.0, 133.7, 123.6, 111.6, 51.4, 39.0, 36.4, 29.8, 28.0, 23.8, 14.0,
12.3. HRMS calculated for C21H30NO4S (M+H) 392.1890, found
392.1888.
2-(adamantane-1-carboxamido)-5-methyl-4-
propylthiophene-3-carboxylic acid (2)
A solution of NaOH (140 mg, 3.5 mmol) in water (2 mL) was
added to a solution of AAT-778 (100 mg, 0.26 mmol) in MeOH
(2 mL) and the mixture was stirred at 80◦C for 3 h. After cooling,
aq. HCl (1 M) was added until a pH of 2 was reached. The
resulting precipitate was filtered and dried to afford the pure
acid (71 mg, 75%) as a white solid. 1H NMR (400 MHz, DMSO-
d6): δ 13.2 (s, 1H), 11.7 (s, 1H), 2.7 (t, J = 5.7 Hz, 2H), 2.2 (s,
3H), 2.0 (m, 3H), 1.9 (m, 7H), 1.7 (m, 7H), 1.4 (m, 2H), 0.9
(t, J = 6.7 Hz, 2H). 13C NMR (100 MHz, DMSO-d6): δ 174.5,
167.8 146.7, 134.3, 123.2, 112.7, 38.9, 36.3, 29.4, 27.9, 23.8, 14.3,
12.4. HRMS calculated for C20H27NO3S (M+H) 362.1784, found
362.1781.
Methyl 2-amino-4,5,6,7-
tetrahydrobenzo[b]thiophene-3-carboxylate (3)
To a suspension of sulfur in MeOH (10 mL) was added methyl
2-cyanoacetate (0.93 mL, 10.54 mmol) and cyclohexanone (0.993
mL, 9.58 mmol). Subsequent addition of diethylamine (0.49 mL,
4.69 mmol) gave a clear solution which was stirred at 50◦C for 12
h. After cooling to room temperature, the reaction mixture was
poured into ice-water and the resulting precipitate was filtered.
The crude product was purified by flash column chromatography
on silica gel using hexane/ethyl acetate (8:2) as eluent to obtain
compound 3 (1.570 g, 78%). 1H NMR (400 MHz, DMSO-d6):
δ 7.20 (s, 2H), 3.66 (s, 3H), 2.57 (t, J = 6.0 Hz, 2H), 2.41 (t,
J = 6.0 Hz, 2H), 1.66 (m, 4H). 13C NMR (100 MHz, DMSO-
d6): δ 165.5, 163.1, 131.5, 115.6, 102.6, 50.4, 26.6, 24.1, 23.0,
22.5. HRMS calculated for C10H13NO2S (M+H) 212.0740, found
212.743.
Methyl 2-3-hydroxyadamantane-1-carboxamido)-
4,5,6,7-tetrahydroben-zo[b]thiophene-3-carboxylate
(AAT-015)
To a solution of 3-hydroxyadamantane-1-carbonyl chloride (108
mg, 0.503 mmol) in dry DCM (2 mL) was added dropwise a
mixture of compound 3 (213 mg, 1.006 mmol) and triethylamine
(70.1 µL, 0.503 mmol) in 0.8 mL of the same solvent. The
reaction mixture was stirred at room temperature for 3 h, diluted
with DCM and extracted with aq. NaHCO3 (saturated solution),
aq. HCl (0.2 M) and brine. The organic layer was dried over
magnesium sulfate and evaporated under reduced pressure. The
crude product was purified by flash column chromatography on
silica gel using hexane/ethyl acetate (6:4) as eluent to yield the title
compound as a white solid (27 mg, 14%). 1H NMR (400 MHz,
CDCl3): δ 11.6 (s, 1H), 3.9 (s, 3H), 2.7 (t, J = 5.6 Hz, 2H), 2.6 (t, J
= 5.6 Hz, 2H), 2.4 (br. m, 2H), 1.9 (m, 6H), 1.8 (m, 8H), 1.6 (m,
2H). 13C NMR (100 MHz, CDCl3): δ 173.8, 167.4, 148.1, 130.7,
126.8, 111.4, 68.4, 51.5, 46.6, 44.2, 37.9, 34.9, 30.4, 26.3, 24.4, 23.0,
22.8. HRMS calculated for C21H27NO4S (M+H) 390.1734, found
390.1729.
2-3-(hydroxyadamantane-1-carboxamido)-4,5,6,7-
tetrahydrobenzo[b]thio-phene-3-carboxylic acid (4)
To a solution of AAT-015 (50 mg, 0.128 mmol) in MeOH (5
mL) was added dropwise NaOH (0.385 mL, 0.385 mmol) and the
reaction mixture was refluxed for 3 h. The reaction mixture was
diluted with water and aq. HCl (1 M) was added until a pH of
2 was reached. The resulting precipitate was filtered and washed
with ice water to give compound 4 (33 mg, 69%). 1H NMR (400
MHz, aceton-d6): δ 11.7 (s, 1H), 2.8 (t, J = 5.7 Hz, 2H), 2.6 (t,
J = 5.7 Hz, 2H), 2.3 (br. m, 2H), 2.1 (s, 1H), 1.9 (m, 6H), 1.7
(m, 8H), 1.6 (m, 2H). 13C NMR (100 MHz, aceton-d6): δ 174.3,
168.2, 149.3, 131.8, 126.8, 112.1, 67.7, 47.4, 45.1, 38.7, 35.8, 31.2,
26.9, 24.8, 23.8, 23.5. HRMS calculated for C20H25NO4S (M+H)
376.1577, found 376.1573.
In vitro Binding Assay
Membrane preparations originating from CHO-K1 cells stably
transfected with either hCB1 or hCB2 (0.5 mg/tube, PerkinElmer,
Massachusetts, US) and tritiated cannabinoid receptor agonist
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CP-55,940 (1.4 nM, CB2 agonist, Perkin Elmer, Boston, US) were
used to determine inhibition constants of AAT-015 and AAT-778
in a competitive in vitro binding assay. A dilution series ranging
from 1 pM to 1 mM in assay buffer (50 mMTRIS, 1 mM EDTA, 3
mMMgCl2 and 0.05% bovine serum albumin, pH adjusted to 7.4)
was prepared for each ligand to be tested. Nonspecific binding
was determined in the presence of AM251 (5 µM, CB1 inverse
agonist, BIOTREND AG, Zürich, CH) and GW405833 (5 µM,
CB2 partial agonist, Sigma Aldrich GmbH, Taufkirchen, DE),
respectively. The samples were incubated at 30◦C for 90 min and
subsequently diluted with ice cold assay buffer (3 mL) in order to
be vacuum-filtered through Whatman GF/C filters (pre-treated
with aq. polyethylenimine, 0.05%). Each sample was washed
twice with ice cold assay buffer (3 mL) and filtered again. After
addition of scintillation cocktail (Ultima Gold, Perkin Elmer),
radioactivity was measured using a Beckman LS 6500 Liquid
Scintillation Counter. IC50 mean values were calculated after
performing three independent experiments, each as triplicate.
The Cheng-Prusoff equation (Cheng and Prusoff, 1973) was used
to calculate the inhibition constants.
Radiochemistry
Radiosynthesis of [11c]AAT-015
[11C]CO2 was produced by proton bombardment of nitrogen gas
fortified with 0.5% oxygen in a Cyclone 18/9 cyclotron (18-MeV;
IBA, Ottignies-Louvain-la-Neuve, Belgium) via the 14N(p,a)11C
nuclear reaction. In a first step, nickel-based catalytic reduction
of [11C]CO2 yielded [
11C]methane which was subsequently
iodinated to give [11C]MeI. In order to prepare [11C]AAT-
015, the methylating agent was bubbled into a reaction mixture
containing precursor 4 (1 mg) and cesium carbonate (5 mg) in
DMF (0.6 mL) and stirred at 90◦C for 3 min. After dilution of the
crude product with water (1.4 mL), purification was performed
by semi-preparative HPLC. The collected radiotracer was diluted
with water (10 mL) and passed through a C18 cartridge (Waters,
pre-conditioned with 5mL EtOH and 5mLwater). After washing
of the cartridge with water (5 mL), the product was eluted with
EtOH (0.5 mL) into a sterile vial and diluted with water for
injection (9.5 mL) to give a final formulation containing 5%
of ethanol. The formulation was used for all in vitro/in vivo
studies. For the purpose of quality control, an aliquot of the
final formulation was injected into the analytical HPLC system.
Identity of the product was confirmed by co-injection and
comparison with the retention time of the standard reference.
The specific activity was calculated by linear regression using
a UV-intensity based calibration curve of standard reference
AAT-015.
Radiosynthesis of [11C]AAT-778
[11C]AAT-778 was prepared according to the radiosynthetic
procedure described in Section Radiosynthesis of [ 11 C]AAT-
015, starting from precursor 2.
In vitro Autoradiography
Autoradiography was performed on rat/mouse spleen tissue.
Sections were prepared in 20 µm thickness using a cryostat
(Cryo-Star NX 50; Thermo Scientific). The tissue slices were
adsorbed to SuperFrost Plus (Menzel) slides and stored at−20◦C
until use. After thawing on ice for 10 min, sections were pre-
incubated in the assay buffer containing 50 mM TRIS, 5 mM
MgCl2, 2.5 mM EDTA, and 0.5% BSA (pH 7.4). Slices were dried
and incubated in a humidified chamber with [11C]AAT-015 (5
nM) or [11C]AAT-778 (5 nM) in assay buffer for 15 min at
room temperature. In order to test for specificity toward CB2, a
solution containing both radiotracer and an excess of CB2 specific
partial agonist GW405833 (10 µM) was prepared and added to
the tissue. The tissue slices were washed twice with assay buffer
(each 2 min) and twice with distilled water (each 5 s) on ice, air
dried, and exposed to a phosphor imager plate for a period of 25
min. The plate was scanned using a BAS5000 reader (Fujifilm,
Dielsdorf, CH).
In vivo PET
PET and CT scans were obtained with a Super Argus PET/CT
tomograph (Sedecal, Madrid, Spain) after injection of [11C]AAT-
015 (10–15 MBq, 0.02–0.10 nmol) into the tail of male Wistar
rats (416 ± 32 g, n = 4) immobilized by isoflurane. Under
baseline conditions, radiotracer accumulation was recorded in
the region of the spleen in dynamic PET acquisition mode over
60 min (n = 2). During this whole time period rats were kept
under anesthesia, body temperature and respiratory rate were
constantly monitored. Under blockade conditions, 1.5 mg/kg
GW405833 was injected shortly before radiotracer application in
two of the four rats. Acquired PET data were reconstructed as
user-defined time frames with a voxel size of 0.3875 × 0.3875 ×
0.775 mm. For anatomical orientation, CT scans were acquired
after each PET scan. Images were evaluated with PMOD v3.4
(PMOD Technologies Inc., Zurich, CH) software. Regions of
interest (spleen, liver, and muscle) were drawn manually using
the PMOD fusion tool. Time activity curves (TACs) for spleen,
liver and muscle were expressed as standardized uptake values
(SUV) which are the decay-corrected radioactivity per cm3
divided by the injected radioactivity dose per gram of body
weight.
RESULTS
Chemistry and Radiochemistry
Thiophene-based reference compounds AAT-778 and
AAT-015 were synthesized starting from commercially
available methyl cyanoacetate and the appropriate ketones
as depicted in Scheme 1. The thiophene amine compounds
1 and 3 were obtained in 11 and 78%, respectively under
the Gewald reaction conditions (Puterová et al., 2010).
Subsequent coupling of 1 and 3 with 1-adamantanecarbonyl
chloride and 3-hydroxyadamantane-1-carbonyl chloride,
respectively, yielded the reference compounds AAT-778
and AAT-015. Saponification of the ester moiety of AAT-
778 afforded precursor 2 for radiolabeling in 75% yield.
Similarly, compound 4 was obtained from AAT-015 in 69%
yield.
The radiosynthesis of [11C]AAT-778 and [11C]AAT-015
was accomplished by methyl ester formation from their
corresponding carboxylic acids with [11C]MeI (Scheme 2). The
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SCHEME 1 | Synthesis of thiophene-based CB2 ligands AAT-778 and AAT-015 and their respective precursors for C-11 radiolabeling.
SCHEME 2 | Radiosynthesis of [11C]AAT-778 and [11C]AAT-015.
obtained radiochemical yields ranged from 12 to 37% (decay
corrected) with specific activities between 96 and 449 GBq/µmol
at the end of synthesis. In all cases, a radiochemical purity
of 99% was attained after semi-preparative HPLC purification
(Figures 1, 2). The total radiosynthesis time from end of
bombardment to the end of synthesis was 40min.
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FIGURE 1 | A typical analytical HPLC profile of [11C]AAT-015 [UV-trace (top) and radio-trace (bottom)].
FIGURE 2 | A typical analytical HPLC profile of [11C]AAT-778 [UV-trace (top) and radio-trace (bottom)].
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In vitro Characterization
Binding affinity studies were performed using membranes stably
transfected with human CB1 and CB2, respectively. A Ki-value
of 4.3 ± 0.7 nM toward CB2 and a 250-fold selectivity over CB1
(Table 1) was obtained for compound AAT-778. We found that
introduction of a polar hydroxyl on the adamantane moiety and
ring closure to form the rather rigid cyclohexene did not impact
the binding affinity and selectivity toward CB2 as shown by the
Ki-value of 3.3 ± 0.5 nM (toward CB2) and 300-fold selectivity
over CB1 for AAT-015. One limitation of our in vitro work is
that besides CB1 we did not investigate the binding affinity of
our ligands to other targets. Furthermore, clogP values depicted
in Table 1 indicate a significant reduction of lipophilicity after
introduction of the hydroxyl group on the adamantane moiety
in AAT-015.
Autoradiography with CD1 mouse and Wistar rat spleen
tissue revealed binding of [11C]AAT-778 to the spleen tissue
in both species under baseline conditions (Figures 3A,C). No
blocking effect was observed using an excess of CB2-specific
ligand GW405833, suggesting that the binding was unspecific
(Figures 3B,D). Similar results were obtained with the less
lipophilic [11C]AAT-015 (Figure 4).
In vivo Characterization
For in vivo evaluation, [11C]AAT-015 was selected due to the
favored lipophilicity profile. Coronal and axial PET/CT slices of
the abdominal region of a representative Wistar rat which was
administered with [11C]AAT-015 are shown in Figure 5. The
spleen is encircled in all the images depicted in Figure 5 and
shows only low uptake of [11C]AAT-015.
Time activity curves (TACs) are depicted in Figure 6 for
the liver, spleen and muscle under baseline (Figure 6A) and
blockade (Figure 6B) conditions. There was no difference in the
spleen uptake of [11C]AAT-015 when comparing the TACs under
baseline and blockade conditions. Radioactivity washout from
the spleen was rather rapid, suggesting a perfusion-like profile
rather than specific accumulation in the target organ. Thus, the
uptake in the spleen was not specific.
DISCUSSION
Thiophene-based structures with high affinity toward CB2 have
been previously reported by Nelson et al. (2012). A series of
derivatives were screened within the context of pain therapy.
TABLE 1 | Ki-values of known CB1/CB2 ligands (entry 1–3; Showalter
et al., 1996; Lan et al., 1999; Valenzano et al., 2005) and newly synthesized
compounds (entry 4, 5).
Ki (hCB2) [nM] Ki (hCB1) [nM] clogP
1. CP-55940 0.7±0.02 0.6± 0.1 5.82
2. AM251 2290±900 7.5± 1.1 5.62
3. GW405833 3.9±1.6 4772± 1676 6.90
4. AAT-778 4.3±0.7 1100± 100 6.00
5. AAT-015 3.3±0.5 1000± 200 4.11
We developed two novel thiophene-based compounds, with an
ester functionality which allows generating the precursors for
C-11 radiolabeling. The designated compounds were obtained
in a two-step synthetic approach involving Gewald reaction
to form the thiophene amine. In the Gewald reaction, methyl
cyanoacetate was treated with the corresponding ketones,
followed by reaction with sulfur to afford thiophene amine
derivatives 1 and 3. In the case of the linear 3-hexanone,
two different regioisomers were obtained which were not
separable by column chromatography. Therefore, an additional
recrystallization step was necessary in order to obtain pure
compound 1 which may partly explain the lower yield when
compared to the synthesis of 2-aminothiophene 3. Coupling of
the amine building blocks to adamantanecarboxylic acid using
HBTU as the coupling reagent did not give the desired amides.
However, amides AAT-015 and AAT-778 could be obtained
by the reaction of the acid chloride with the corresponding
thiophene amines. Subsequently, saponification of the ester
intermediates gave the acid precursors in good chemical
yields.
Binding affinity studies revealed that the introduction of
the hydrophilic OH-group at the adamantane moiety did not
have any influence on the affinity toward the CB2 receptor
since similar Ki-values were obtained for both AAT-015 and
AAT-0778. Furthermore, the introduction of rigidity by ring-
closure did not affect the binding affinity, which enlarges the
compound selection and simplifies compound synthesis. As
expected, the lipophilicity of AAT-015 was significantly reduced
to 4.11 compared to 6.00 for AAT-778, which is highly desired.
Carbon-11 radiolabelings of the acid precursors were carried out
under similar conditions for both tracers and yielded comparable
results in terms of radiochemical yield and purity as well as
specific activity. In autoradiography studies with rodent spleen
tissue [11C]AAT-778 exhibited high unspecific binding. We
speculate that this high unspecific binding is related to the high
lipophilicity of the molecule. In order to reduce this unspecific
binding, we modified AAT-778 by introducing a hydroxyl moiety
on the adamantine ring to deliver AAT-015. However, despite the
significant reduction of clogP, [11C]AAT-015 still revealed a high
unspecific binding in mouse and rat spleen tissues. PET studies
of [11C]AAT-015 confirmed the lack of specificity toward CB2-
positive spleen tissue in vivo. Possible reasons for the described
in vivo results might include high plasma protein binding and
rapid metabolism. The ester functionality can be cleaved by the
action of carboxylesterases which are present in the plasma. This
would, however, lead to a loss of the radiolabel from the core
structure.
In conclusion, the novel thiophene-based radiotracers
[11C]AAT-778 and [11C]AAT-015 are not suitable CB2
PET tracers due to the lack of specificity for CB2-positive
spleen tissue and therefore were not further evaluated
in neuroinflammatory animal models. Nonetheless,
the high in vitro binding affinity toward CB2 as well
as the high selectivity over CB1 makes this class of
compounds interesting for further structural optimization
toward improved physicochemical and pharmacological
properties.
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FIGURE 3 | The autoradiography results obtained with 5 nM [11C]AAT-778 using spleen tissue sections. (A) Mouse spleen under baseline condition; (B)
Mouse spleen under blockade conditions (10 µM GW405833); (C) Rat spleen under baseline conditions; (D) Rat spleen under blockade conditions (10 µM
GW405833); n = 2.
FIGURE 4 | The autoradiography results obtained with 5 nM [11C]AAT-015 using spleen tissue sections. (A) Mouse spleen under baseline condition; (B)
Mouse spleen under blockade conditions (10 µM GW405833); (C) Rat spleen under baseline conditions; (D) Rat spleen under blockade conditions (10 µM
GW405833); n = 2.
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FIGURE 5 | Rat spleen PET/CT images after injection of [11C]AAT-015 (averaged 0–60 min post injection). (A) Coronal and axial slices of the abdominal
region. Spleen is encircled in the CT and PET/CT images, demonstrating low uptake of [11C]AAT-015. SUV max = 4. (B) Maximal intensity projection (MIP) images of
the abdominal region under baseline (same rat as in A) and blockade conditions (injection of 1.5 mg/kg GW405833 shortly before radiotracer). Spleen is encircled. Li,
liver; Ki, kidney; Int, intestine. SUV max = 6.
FIGURE 6 | Representative time activity curves (TACs) showing the standardized uptake values (SUV) of spleen, liver, and muscle in the time course of
60 min after injection of [11C]AAT-015 into Wistar rats. (A) Injection of tracer only; (B) Injection of tracer and 1.5 mg/kg GW405833 (shortly before tracer).
AUTHOR CONTRIBUTIONS
AH performed the organic synthesis of precursor 4 and
reference compound AAT-015 and conducted the IC50 studies
with AAT-015. He further performed the radiosynthesis
and autoradiography studies with [11C]AAT-015 and wrote
the manuscript. AM planned and evaluated the in vivo
experiments and helped writing the manuscript. RS performed
the radiosynthesis and autoradiography with [11C]AAT-778.
MW was involved in result discussions and revised the
manuscript. CM and AL synthesized precursor 2 and reference
compound AAT-778 and determined the Ki-value of AAT-778.
Frontiers in Neuroscience | www.frontiersin.org 9 July 2016 | Volume 10 | Article 350
Haider et al. Thiophene-Based CB2 PET Radiotracers
RS revised and approved the manuscript. LM and SM planned
and organized the whole project and approved the manuscript.
ACKNOWLEDGMENTS
We would like to express our gratitude to Bruno Mancosu
for his technical support with the carbon-11 module
and to Claudia Keller for performing the PET/CT
scans. Furthermore, we thank Hazem Ahmed for the
support on the manuscript, Anna Katherina Boninsegni
and Melinda Glier for the assistance in IC50 and
autoradiography studies. The authors also thank the Swiss
ALS Association and the Vontobel Foundation for the financial
support.
REFERENCES
Benito, C., Tolón, R. M., Pazos, M. R., Núñez, E., Castillo, A. I., and Romero,
J. (2008). Cannabinoid CB2 receptors in human brain inflammation. J.
Pharmacol. 153, 277–285. doi: 10.1038/sj.bjp.0707505
Cheng, Y., and Prusoff,W. H. (1973). Relationship between the inhibition constant
(K1) and the concentration of inhibitor which causes 50 per cent inhibition
(I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099–3108. doi:
10.1016/0006-2952(73)90196-2
Chin, C. L., Tovcimak, A. E., Hradil, V. P., Seifert, T. R., Hollingsworth, P. R.,
Chandran, P., et al. (2008). Differential effects of cannabinoid receptor agonists
on regional brain activity using pharmacological MRI. Br. J. Pharmacol. 153,
367–379. doi: 10.1038/sj.bjp.0707506
Evens, N., Bosier, B., Lavey, B. J., Kozlowski, J. A., Vermaelen, P., and Baudemprez,
L. (2008). Labelling and biological evaluation of [11C]methoxy-Sch225336: a
radioligand for the cannabinoid-type 2 receptor. Nucl. Med. Biol. 5, 793–800,
doi: 10.1016/j.nucmedbio.2008.07.004
Herkenham,M., Lynn, A. B., Johnson,M. R.,Melvin, L. S., de Costa, B. R., and Rice,
K. C. (1991). Characterization and localization of cannabinoid receptors in rat
brain: a quantitative in vitro autoradiographic study. J. Neurosci. 11, 563–583.
Hortala, L., Arnaud, J., Roux, P., Oustric, D., Boulu, L., and Oury-Donat, F. (2014).
Synthesis and preliminary evaluation of a new fluorine-18 labelled triazine
derivative for PET imaging of cannabinoid CB2 receptor. Bioorg. Med. Chem.
Lett. 24, 283–287. doi: 10.1016/j.bmcl.2013.11.023
Horti, A. G., Gao, Y., Ravert, H. T., Finley, P., Valentine, H., and Wong, D.
F. (2010). Synthesis and biodistribution of [11C]A-836339, a new potential
radioligand for PET imaging of cannabinoid type 2 receptors (CB2). Bioorg.
Med. Chem. 18, 5202–5207. doi: 10.1016/j.bmc.2010.05.058
Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S. R., and McCallion, D. (1999).
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor
antagonists. J. Med. Chem. 42, 769–776. doi: 10.1021/jm980363y
Mackie, K. (2008). Cannabinoid receptors: where they are and what they do. J.
Neuroendocrinol. 20, 1365–2826. doi: 10.1111/j.1365-2826.2008.01671.x
Maresz, K., Carrier, E. J., Ponomarev, E. D., Hillard, C. J., and Dittel, B. N. (2005).
Modulation of the cannabinoid CB2 receptor in microglial cells in response
to inflammatory stimuli. J. Neurochem. 95, 437–445. doi: 10.1111/j.1471-
4159.2005.03380.x
Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C., and Bonner, T. I.
(1990). Structure of a cannabinoid receptor and functional expression of the
cloned cDNA. Nature 346, 561–564.
Mu, L., Bieri, D., Slavik, R., Drandarov, K., Müller, A., Cermak, S., et al.
(2013). Radiolabeling and in vitro/in vivo evaluation of N-(1-adamantyl)-
8-methoxy-4-oxo-1-phenyl- 1,4-dihydroquinoline-3-carboxamide as a PET
probe for imaging cannabinoid type 2 receptor. J. Neurochem. 126, 616–624.
doi: 10.1111/jnc.12354
Mu, L., Slavik, R., Müller, A., Popaj, K., Cermak, S., and Weber, M. (2014).
Synthesis and preliminary evaluation of a 2-oxoquinoline carboxylic acid
derivative for pet imaging the cannabinoid type 2 receptor. Pharmaceuticals
(Basel) 7, 339–352. doi: 10.3390/ph7030339
Nelson, D. W., Frost, J. M., Tietje, K. R., Florjancic, A. S., Ryther, K., and Carroll,
W. A. (2012). Synthesis and evaluation of 2-amido-3-carboxamide thiophene
CB2 receptor agonists for pain management. Bioorg. Med. Chem. Lett. 22,
2604–2608. doi: 10.1016/j.bmcl.2012.01.121
Onaivi, E. S. (2009). Cannabinoid receptors in brain: pharmacogenetics,
neuropharmacology, neurotoxicology, and potential therapeutic applications.
Int. Rev. Neurobiol. 88, 335–369. doi: 10.1016/s0074-7742(09)88012-4
Pertwee, R. G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors.
Pharmacol. Ther. 74, 129–180. doi: 10.1016/S0163-7258(97)82001-3
Pertwee, R. G. (2005). The therapeutic potential of drugs that target cannabinoid
receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J.
7, 625–654. doi: 10.1208/aapsj070364
Puterová, Z., Krutošíková, A., and Véghc, D. (2010). Gewald reaction: synthesis,
properties and applications of substituted 2-aminothiophenes. Arch. Organ.
Chem. 2010, 209–246. doi: 10.3998/ark.5550190.0011.105
Rom, S., and Persidsky, Y. (2013). Cannabinoid receptors: where they are and
what they do. J. Neuroimmun. Pharmacol. 8, 608–620. doi: 10.1007/s11481-013-
9445-9
Showalter, V. M., Compton, D. R., Martin, B. R., and Abood, M. E. (1996).
Evaluation of binding in a transfected cell line expressing a peripheral
cannabinoid receptor (CB2): identification of cannabinoid receptor subtype
selective ligands. J. Pharmacol. Exp. Ther. 278, 989–999.
Slavik, R., Grether, U., Müller Herde, A., Gobbi, L., Fingerle, J., Ullmer, C., et al.
(2015b). Discovery of a high affinity and selective pyridine analog as a potential
positron emission tomography imaging agent for cannabinoid type 2 receptor.
J.Med. Chem. 58, 4266−4277. doi: 10.1021/acs.jmedchem.5b00283
Slavik, R., Herde, A. M., Bieri, D., Weber, M., Schibli, R., Krämer, S. D., et al.
(2015a). Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline
derivatives as PET tracers for imaging cannabinoid type 2 receptor. Eur. J. Med.
Chem. 92, 554–564. doi: 10.1016/j.ejmech.2015.01.028
Valenzano, K. J., Tafesse, L., Lee, G., Harrison, J. E., Boulet, J. M., Gottshall, S. L.,
Mark, L., et al. (2005). Pharmacological and pharmacokinetic characterization
of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of
acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 48,
658–672. doi: 10.1016/j.neuropharm.2004.12.008
Vandeputte, C., Evens, N., Toelen, J., Deroose, C. M., Bosier, B., and
Ibrahimi, A. (2011). A PET brain reporter gene system based on type 2
cannabinoid receptors. J. Nucl. Med. 2, 1102–1109. doi: 10.2967/jnumed.110.0
84426
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie,
K., et al. (2005). Identification and functional characterization of brainstem
cannabinoid CB2 receptors. Science 310, 329–332. doi: 10.1126/science.1115740
Zinman, L., and Cudkowicz, M. (2011). Emerging targets and treatments in
amyotrophic lateral sclerosis. Lancet Neurol. 10, 481–490. doi: 10.1016/S1474-
4422(11)70024-2
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Haider, Müller Herde, Slavik, Weber, Mugnaini, Ligresti, Schibli,
Mu and Mensah Ametamey. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 10 July 2016 | Volume 10 | Article 350
